Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 1999

View Archived Issues

Novel MSI delivery system tested in breakthrough pain therapy

Vitamin D analogue Ro-25-6760 is a promising treatment for colon cancer

Company Profile: Redox

Vion and EPTTCO to develop new cancer treatments based on TAPET delivery system

Second HIV fusion inhibitor developed at Trimeris given fast track designation

Lundbeck: Annual Report 1998

Ophidian: Q2 1999 highlights

New vitronectin receptor ligands emerge from collaborative research at HMR and Genentech

Neuropeptide Y antagonists specifically claimed for use in cardiovascular disorders

Corvas and Schering-Plough extend HCV agreement

Bayer's new CETP inhibitors described in recently published patent

Tokyo Tanabe discloses new antimuscarinic agents

Onyvax licenses anticancer vaccine from CRCT

Antirotavirus polymers in development at GelTex

Abbott prepares semisynthetic rapamycin analogues with reduced half-lives

ImClone commences second phase III trial of C225

SmithKline Beecham describes new series of CCR5 receptor modulators

Preliminary clinical results reported at ASCO for Tularik microtubule inhibitor

XR-9576: first clinical results indicate efficacy, safety and favorable pharmacokinetics

News from ASCO: Genta's G-3139 is effective in treating various cancer types

Immune Response to collaborate with Univ. of Maryland on chemokine research

ASCO highlights: phase I clinical trial results with oral R-115777 alone and in combination regimen

Introgen Therapeutics and RPR Gencell sign CRADA with NCI

Takeda reports discovery of TAK-779, a potent anti-HIV agent with a novel mechanism

Novartis presents first clinical results for Abl tyrosine kinase inhibitor CGP-57148

Novel intranasally administered small peptide shows good efficacy and safety in AIDS-related KS

News from ASCO: clinical pharmacology of Bay-12-9566 assessed in cancer patients

Alcon launches emedastine in U.K. for treatment of seasonal allergic conjunctivitis

ZD-0473 exhibits favorable toxicity profile in phase I studies in solid tumor patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...